New Delhi: In yet another setback for multinational pharmaceutical companies’ intellectual property rights, the patents office on Monday rejected Pfizer Inc.’s patent claim on Sutent (sunitinib)—a treatment for liver and kidney cancer.
The patent office has granted Cipla Ltd rights to manufacture generic version of the drug on the grounds that Pfizer’s patent does not involve any inventive step. The patent litigation comes against the backdrop of a string of patent-related cases being fought in different courts related to the amended Indian patent law. Among them, a verdict on Novartis AG's case on a patent for its leukemia treatment Glivec (imatinib) is due any day.
This is a corrected version of an earlier story.